Fang X, et al. Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial. EClinicalMedicine. 2023 Jul 27;62:102123. doi: 10.1016/j.eclinm.2023.102123...
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2022, 7: 38-...
针对结直肠癌免疫治疗,白莉教授说道,KEYNOTE-016研究确定了MSI-H/dMMR是转移性结直肠癌免疫治疗的分子标志物,近些年关于结直肠癌免疫治疗进展亦主要针对此类患者,但对于在结直肠癌中占比更高的微卫星稳定(MSS)/错配修复正常(pMMR)患者而言,是否合适接受免疫治疗未来仍需探索。 小分子抗血管生成靶向药物未来或可大放...
[2]KRYSTAL-1:Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. 2021 ESMO. Abstract LBA 6. [3]Diaz LA Jr, Shiu...
在结直肠癌患者中,微卫星稳定/错配基因修复熟练(MSS/pMMR)型超过90%,其余则为微卫星不稳定/错配基因修复缺陷(MSI-H/dMMR),免疫治疗对于后者的益处已被充分证实。然而,MSS/pMMR型结直肠癌患者的免疫治疗前路如何?让我们跟随华中科技大学附...
本文编译自Cancer Treatment Reviews期刊上的一篇文章：Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer。在结直肠癌（CRC）中，ICIs的治疗效果，只惠及了dMMR/MSI-H的人群(≈5%）。获益的原因在于这部分患者，具有高...
本文编译自Cancer Treatment Reviews期刊上的一篇文章:Regorafenib in combination with immunecheckpointinhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer。 在结直肠癌(CRC)中,ICIs的治疗效果,只惠及了dMMR/MSI-H的人群(≈5%)。获益的原因在于这部分患者,具有高突变/新抗...
MSI- H/dMMR（3.5%-5%）、BRAF V600E突变（5%-9%）、KRAS突变和NRAS外显子2、3和4突变（45%-55%）。KRAS和NRAS突变与BRAF V600E突变通常是互斥的。KRAS G12C突变估计在所有mCRC中为3%。ERBB2在mCRC中很少扩增和/或过度表达，估计为3%（RAS和BRAF野生型肿瘤中为5-7%）。BRAF非V600E突变和MET扩增...
was used to evaluate the expression of immune checkpoint molecules in the tumor core and at the invasive margin.#Data analysis showed the predominance of PD-L1 (p=0.011), CTLA-4 (p=0.004), and LAG-3 (p=0.013) expression at the invasive margin of dMMR carcinomas compared to pMMR ...
近日，南方医科大学/广东省分子肿瘤病理学重点实验室研究团队在国际权威期刊《Oncogene》上发表了题为“ASCL2 induces an immune excluded microenvironment by activating cancer-associated fibroblasts in microsatellite stable colorectal cancer”的研究论文，该研究报道了两种不同的ASCL2在pMMR/MSS和dMMR/MSI-H crc中的...